• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

静脉注射丙种球蛋白治疗艰难梭菌毒素引起的慢性复发性结肠炎。

Treatment with intravenously administered gamma globulin of chronic relapsing colitis induced by Clostridium difficile toxin.

作者信息

Leung D Y, Kelly C P, Boguniewicz M, Pothoulakis C, LaMont J T, Flores A

机构信息

Division of Pediatric Allergy-Immunology, National Jewish Center for Immunology and Respiratory Medicine, Denver, Colorado 80206.

出版信息

J Pediatr. 1991 Apr;118(4 Pt 1):633-7. doi: 10.1016/s0022-3476(05)83393-1.

DOI:10.1016/s0022-3476(05)83393-1
PMID:1901084
Abstract

We tested the hypothesis that children with chronic relapsing colitis induced by Clostridium difficile toxin have defective antibody responses to C. difficile toxins as a cause of their underlying illness. Six such children were tested for serum IgG and IgA antibody to C. difficile toxin A. These six children had lower IgG anti-toxin A levels than 24 healthy children (p = 0.026) and 18 healthy adults (p = 0.0008). Five patients treated with 400 mg intravenously administered gamma-globulin per kilogram every 3 weeks had significant increases in IgG (p = 0.01) but not IgA anti-toxin A (p = 0.406) levels, and all five had clinical resolution of their gastrointestinal symptoms as well as clearing of C. difficile cytotoxin B from their stools. These observations suggest that a deficiency of IgG anti-toxin A may predispose children to the development of chronic relapsing C. difficile-induced colitis. In such cases, intravenous gamma-globulin therapy may be effective in producing clinical remission.

摘要

我们检验了这样一个假设

由艰难梭菌毒素引起的慢性复发性结肠炎患儿对艰难梭菌毒素的抗体反应存在缺陷,这是其潜在疾病的病因。对6名此类患儿进行了针对艰难梭菌毒素A的血清IgG和IgA抗体检测。这6名患儿的IgG抗毒素A水平低于24名健康儿童(p = 0.026)和18名健康成人(p = 0.0008)。5名每3周静脉注射每千克400毫克丙种球蛋白的患者,其IgG(p = 0.01)水平显著升高,但IgA抗毒素A水平(p = 0.406)未升高,且所有5名患者的胃肠道症状均有临床缓解,粪便中的艰难梭菌细胞毒素B也清除。这些观察结果表明,IgG抗毒素A缺乏可能使儿童易患慢性复发性艰难梭菌诱导的结肠炎。在这种情况下,静脉注射丙种球蛋白治疗可能有效实现临床缓解。

相似文献

1
Treatment with intravenously administered gamma globulin of chronic relapsing colitis induced by Clostridium difficile toxin.静脉注射丙种球蛋白治疗艰难梭菌毒素引起的慢性复发性结肠炎。
J Pediatr. 1991 Apr;118(4 Pt 1):633-7. doi: 10.1016/s0022-3476(05)83393-1.
2
Gamma globulin administration in relapsing Clostridium difficile-induced pseudomembranous colitis with a defective antibody response to toxin A.在复发性艰难梭菌诱导的假膜性结肠炎中给予丙种球蛋白,其对毒素A的抗体反应存在缺陷。
Acta Clin Belg. 1995;50(1):36-9. doi: 10.1080/17843286.1995.11718419.
3
Intravenous immunoglobulin therapy for severe Clostridium difficile colitis.静脉注射免疫球蛋白治疗重症艰难梭菌结肠炎
Gut. 1997 Sep;41(3):366-70. doi: 10.1136/gut.41.3.366.
4
Antigenicity of amino-acid sequences from Clostridium difficile toxin B.艰难梭菌毒素B氨基酸序列的抗原性
J Med Microbiol. 1996 Jun;44(6):464-74. doi: 10.1099/00222615-44-6-464.
5
Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A.艰难梭菌无症状携带与抗毒素A的IgG抗体血清水平
N Engl J Med. 2000 Feb 10;342(6):390-7. doi: 10.1056/NEJM200002103420604.
6
Immunoglobulin G directed against toxins A and B of Clostridium difficile in the general population and patients with antibiotic-associated diarrhea.普通人群及抗生素相关性腹泻患者体内针对艰难梭菌毒素A和毒素B的免疫球蛋白G
Diagn Microbiol Infect Dis. 1994 Apr;18(4):205-9. doi: 10.1016/0732-8893(94)90021-3.
7
Recurrent Clostridium difficile infection in a patient with selective IgG1 deficiency treated with intravenous immune globulin and Saccharomyces boulardii.一名选择性IgG1缺乏症患者接受静脉注射免疫球蛋白和布拉酵母菌治疗后出现复发性艰难梭菌感染
Clin Infect Dis. 1995 Jun;20 Suppl 2:S266-8. doi: 10.1093/clinids/20.supplement_2.s266.
8
Serum antibody response to toxins A and B of Clostridium difficile.针对艰难梭菌毒素A和毒素B的血清抗体反应。
J Infect Dis. 1983 Jul;148(1):93-100. doi: 10.1093/infdis/148.1.93.
9
Systemic and mucosal antibody responses to toxin A in patients infected with Clostridium difficile.艰难梭菌感染患者对毒素A的全身和黏膜抗体反应。
J Infect Dis. 1992 Dec;166(6):1287-94. doi: 10.1093/infdis/166.6.1287.
10
Association between IgG2 and IgG3 subclass responses to toxin A and recurrent Clostridium difficile-associated disease.IgG2和IgG3亚类对毒素A的反应与复发性艰难梭菌相关性疾病之间的关联。
Clin Gastroenterol Hepatol. 2007 Jun;5(6):707-13. doi: 10.1016/j.cgh.2007.02.025.

引用本文的文献

1
Case Series: Efficacy of Polyclonal Intravenous Immunoglobulin for Refractory Infection.病例系列:多克隆静脉注射免疫球蛋白治疗难治性感染的疗效
Antibodies (Basel). 2024 Apr 1;13(2):26. doi: 10.3390/antib13020026.
2
Clostridioides difficile Infection: A Clinical Review of Pathogenesis, Clinical Considerations, and Treatment Strategies.艰难梭菌感染:发病机制、临床考量及治疗策略的临床综述
Cureus. 2023 Dec 27;15(12):e51167. doi: 10.7759/cureus.51167. eCollection 2023 Dec.
3
Immunization Strategies Against Clostridioides difficile.针对艰难梭菌的免疫策略。
Adv Exp Med Biol. 2024;1435:117-150. doi: 10.1007/978-3-031-42108-2_7.
4
Polyvalent human immunoglobulin for infectious diseases: Potential to circumvent antimicrobial resistance.多价人免疫球蛋白治疗传染病:克服抗菌药物耐药性的潜力。
Front Immunol. 2023 Jan 9;13:987231. doi: 10.3389/fimmu.2022.987231. eCollection 2022.
5
Oral Immunotherapy With Human Secretory Immunoglobulin A Improves Survival in the Hamster Model of Clostridioides difficile Infection.口服人分泌型免疫球蛋白 A 治疗可提高仓鼠艰难梭菌感染模型的生存率。
J Infect Dis. 2021 Oct 28;224(8):1394-1397. doi: 10.1093/infdis/jiab087.
6
Are Antimotility Agents Safe for Use in Infections? Results From an Observational Study in Malignant Hematology Patients.止泻药用于感染性疾病是否安全?一项针对恶性血液病患者的观察性研究结果
Mayo Clin Proc Innov Qual Outcomes. 2020 Nov 5;4(6):792-800. doi: 10.1016/j.mayocpiqo.2020.06.005. eCollection 2020 Dec.
7
Anti-toxin antibody is not associated with recurrent Clostridium difficile infection.抗毒素抗体与复发性艰难梭菌感染无关。
Anaerobe. 2021 Feb;67:102299. doi: 10.1016/j.anaerobe.2020.102299. Epub 2020 Nov 21.
8
Enterotoxic Clostridia: Infections.肠毒素梭菌:感染。
Microbiol Spectr. 2019 May;7(3). doi: 10.1128/microbiolspec.GPP3-0015-2018.
9
Recurrent Infection: Risk Factors, Treatment, and Prevention.反复感染:危险因素、治疗和预防。
Gut Liver. 2019 Jan 15;13(1):16-24. doi: 10.5009/gnl18071.
10
Application of Antibody-Mediated Therapy for Treatment and Prevention of Infection.抗体介导疗法在感染治疗与预防中的应用。
Front Microbiol. 2018 Jun 25;9:1382. doi: 10.3389/fmicb.2018.01382. eCollection 2018.